相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients
Philip J. F. Troke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease
Christoph Welsch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
Jean-Michel Pawlotsky et al.
ANTIVIRAL THERAPY (2012)
Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy
Oliver Lenz et al.
GASTROENTEROLOGY (2012)
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052
Jin-Hua Sun et al.
HEPATOLOGY (2012)
Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy
Evguenia S. Svarovskaia et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
CHARACTERIZATION OF HCV VARIANTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS ADMINISTERED THE COMBINATION OF TVR AND VX-222 IN DUAL ARMS OF ZENITH STUDY
E. Z. Zhang et al.
JOURNAL OF HEPATOLOGY (2012)
ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2012)
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
Tara L. Kieffer et al.
PLOS ONE (2012)
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
Stefan Zeuzem et al.
GASTROENTEROLOGY (2011)
Retreatment with Telaprevir Combination Therapy in Hepatitis C Patients with Well-Characterized Prior Treatment Response
Andrew J. Muir et al.
HEPATOLOGY (2011)
Treatment Failure and Resistance with Direct-Acting Antiviral Drugs Against Hepatitis C Virus
Jean-Michel Pawlotsky
HEPATOLOGY (2011)
CHARACTERIZATION OF VIRAL RESISTANCE MUTATIONS IN GENOTYPE 1 HCV PATIENTS RECEIVING COMBINATION THERAPY WITH A PROTEASE INHIBITOR AND A POLYMERASE INHIBITOR WITH OR WITHOUT RIBAVIRIN
H. Mo et al.
JOURNAL OF HEPATOLOGY (2011)
Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA
Angela M. Lam et al.
JOURNAL OF VIROLOGY (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
Megan H. Powdrill et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
Andrew Bae et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
Bambang S. Adiwijaya et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection
Pierre L. Beaulieu
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
Samir Ali et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
Ann D. Kwong et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Genotypic analysis of HCVNS5B variants selected from patients treated with VCH-759
O. Nicolas et al.
JOURNAL OF HEPATOLOGY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
Stephanie T. Shi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The mechanism of action of β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidme involves a second metabolic pathway leading to β-D-2'-deoxy-2-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
Eisuke Murakami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro
Liangjun Lu et al.
ANTIVIRAL RESEARCH (2007)
Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors
Frederik Pauwels et al.
JOURNAL OF VIROLOGY (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro
Gennadiy Koev et al.
ANTIVIRAL RESEARCH (2007)
In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance
Sophie Le Pogam et al.
VIROLOGY (2006)
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
G Kukolj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure
F Ceccherini-Silberstein et al.
AIDS (2004)
Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs
SS Carroll et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
